焦磷酸钙沉积病患者冠状动脉钙化与动脉粥样硬化性心血管疾病风险评分
在学术医疗中心1991—2022年横断面分析中,756例软骨钙化患者与1554例按年龄性别2:1匹配的无软骨钙化对照相比,未校正Agatston评分无显著差异(均值359.1 vs 297.1,P=0.08),但软骨钙化组10年ASCVD高风险评分显著更常见(P<0.01)。
要点
- 软骨钙化患者未校正冠状动脉钙化Agatston评分与匹配对照无显著差异(均值359.1 vs 297.1,P=0.08)。
- 软骨钙化组10年ASCVD高风险评分较对照显著更常见(P<0.01)。
- 作者认为冠状动脉钙化之外的因素可能参与焦磷酸钙沉积病患者心血管事件增加。
核心结论
- 冠状动脉钙化评估的冠状动脉粥样硬化负荷在软骨钙化患者与匹配对照间无显著差异,但软骨钙化组10年ASCVD风险评分更高,提示冠状动脉钙化之外的因素可能参与焦磷酸钙沉积病患者心血管事件率增加。
研究设计与样本
- 学术医疗中心1991—2022年横断面分析,在常规诊疗中接受Agatston评分者中定义软骨钙化组,对照按年龄和性别2:1匹配,主要分析排除他汀使用者。
主要发现
- 756例软骨钙化患者匹配1554例对照,平均年龄68岁,女性53%,两队列心血管危险因素负担均高且他汀使用不频繁。
- 未校正Agatston评分在软骨钙化组均值359.1(s.d. 737.9),匹配对照均值297.1(s.d. 644.9),差异无统计学显著(P=0.08)。
- 10年ASCVD高风险评分在软骨钙化组较对照显著更常见(P<0.01)。
关键数值与推荐
- Agatston评分用于评估冠状动脉钙化,10年ASCVD风险评分分为低、临界/中等或高三档。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease is associated with an increased risk for cardiovascular (CV) events. We examined the atherosclerotic burden by coronary artery calcium (CAC) scores (Agatston score) and compared 10-year atherosclerotic CV disease (ASCVD) risk scores in patients with vs without chondrocalcinosis, a radiographic marker of CPPD. METHODS: We performed a cross-sectional analysis at an academic medical centre, 1991-2022. Among all patients with an Agatston score in routine care, we defined a cohort with chondrocalcinosis detected before the CAC scan. Comparators without chondrocalcinosis were matched 2:1 on age and sex-the primary analysis excluded statin users. We compared Agatston scores between the chondrocalcinosis cohort and comparators. We also tested for differences between cohorts in 10-year ASCVD risk score frequencies (low, borderline/intermediate or high). RESULTS: 756 patients with chondrocalcinosis were matched to 1554 comparators (mean age 68 years, 53% female). CV risk factor burden was high in both cohorts, and statin use was infrequent. The unadjusted Agatston score was non-significantly higher in the chondrocalcinosis cohort (mean 359.1, s.d. 737.9) than in matched comparators (mean 297.1, s.d. 644.9) (P = 0.08). High 10-year ASCVD risk scores were significantly more common in the chondrocalcinosis cohort than comparators (P < 0.01). CONCLUSION: Coronary atherosclerosis burden by CAC was not significantly different between patients with chondrocalcinosis and matched comparators, though 10-year ASCVD risk scores were higher in the chondrocalcinosis cohort, suggesting that factors beyond coronary artery calcification contribute to the increased CV event rate in patients with CPPD disease.
引用
- Tedeschi SK, Hayashi K, Guan H, et al. Coronary artery calcium and atherosclerotic cardiovascular disease risk scores in patients with calcium pyrophosphate deposition disease. Rheumatology (Oxford). 2025. PMID: 39666953. doi:10.1093/rheumatology/keae655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。